April 28, 2014 08:48 AM Eastern Daylight Time
Provectus Biopharmaceuticals, Inc. Retains Roberti+White, LLC as Public Policy Consultants
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) ( http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has retained the services of Roberti+White, LLC as its public policy consultants.
Roberti+White will assist Provectus in Commercialization Strategy of PV-10 by developing and implementing a plan to expand its congressional outreach to key Members of Congress, Congressional Committees and Caucuses that address healthcare issues. Roberti+White will also advise on Food and Drug Administration (FDA) regulatory issues as they arise and develop action plans in response to such developments. When conditions warrant, Roberti+White will also assist Provectus in its development of an effective Medicare coverage, coding and payment strategy for its products in development.
Dr. Craig Dees, PhD, CEO of Provectus, said, “With this consulting agreement, Provectus continues to create the infrastructure that we will need to bring PV-10 and our other preparations to market as quickly as possible. Although FDA approval of our PV-10 treatment for locally advanced cutaneous melanoma is by no means assured, we need to be proactive and cannot wait for a firm decision before acting as we are. Roberti+White have made a name for themselves in public policy circles especially in matters of healthcare, drug regulation and the political terrain of Washington. Given that their client list includes AARP and Novartis among others, we are confident that we have entrusted Provectus’ interests here to the best hands possible, and we look forward to working with Roberti+White.”
Richard White, Managing Partner of Roberti+White, said, “We are pleased to join Provectus in its fight against cancer, and especially with regard to PV-10 as a treatment for locally advanced cutaneous melanoma. We believe that we bring a great deal of necessary expertise and insight to help Provectus navigate the regulatory environment in the most efficient and effective way for the benefit of its shareholders and more importantly for those patients who will benefit from its potentially breakthrough and life saving treatments.”
About Roberti+White, LLC
Roberti+White is a bipartisan federal government affairs and public relations firm based in Washington, DC and with offices in New York City. The principals at the firm have decades of experience advising clients on coverage and reimbursement policy and FDA drug approval issues. The firm currently represents some of the largest Fortune 100 companies including leaders in pharmaceuticals and health care.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. |
